ClinicalTrials.gg
CompletedNCT04844892PIRATUpdated Oct 5, 2023

Phrenic Nerve Stimulation-Induced Lung ReAeration Trial

An interventional study of Lungpacer PROTECT Diaphragm Pacing Therapy in Acute Respiratory Distress Syndrome and Ventilation Therapy; Complications, sponsored by Lungpacer Medical Inc.. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.

Enrollment
99th of 118
13 · median 50
Started
2021
with 15 others
No phase
77 of 217
14 open now
Registered
147th of 217
by date

Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 99th largest by enrollment of the 118 interventional ones that give a count, is one of 16 that started in 2021, is one of 77 with no phase, and was the 147th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Respiratory Distress Syndrome with a site in France, or all of them as a file.
02

Study summary

The Lungpacer PROTECT Diaphragm Pacing Therapy System (DPTS) is a temporary, percutaneously-placed, transvenous, phrenic nerve-stimulating device intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients. The purpose of the PROTECT DPTS is to improve gas exchange, regional lung ventilation, and hemodynamics, and decrease atelectasis in patients presenting with acute respiratory distress syndrome (ARDS).

Read the detailed description

The PIRAT clinical study is intended to assess the feasibility, safety and effectiveness of transvenous phrenic-nerve-stimulating diaphragm pacing on clinical outcomes in mechanically ventilated patients. By delivering electrical stimulation to the phrenic nerves, which in turn causes the diaphragm muscle to contract, the PROTECT DPTS is intended to protect the diaphragm from atrophy and preserve lung mechanics to reduce lung inflammation and injury associated with short-term mechanical ventilation. Sustained lung and diaphragm health during early mechanical ventilation is expected to reduce the risk of comorbidities, improve clinical outcomes such as weaning success, and thereby reduce the number of patients who require prolonged mechanical ventilation.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Ventilation Therapy; Complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years or older
  • Have been mechanically ventilated due to moderate ARDS for 48-120h
  • Have a PaO2/FiO2 ratio \< 200 and > 100 at the time of screening with PEEP ≥ 5 cmH2O
  • Are expected to remain on mechanical ventilation ≥ 48 hours
  • Are under continuous sedation with Richmond Agitation Sedation Scale (RASS) ≤ -3

Exclusion criteria

Exclusion Criteria:

  • Septic shock with hemodynamic instability (norepinephrine or epinephrine \< 0.5 gamma/kg/min)
  • Catheter access to left subclavian vein deemed impossible
  • Use of neuromuscular blocking agents within last 12 hours
  • Bacteremia within the last 48 hours or uncontrolled source of infection
  • Currently on ECMO
  • Enrolled in any other study of an drug or device, which may affect the outcomes of the current study
  • Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles
  • >45 kg/m2
  • Known or suspected phrenic nerve paralysis
  • Any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer PROTECT DPTS, including neurological pacing/stimulator devices and cardiac pacemakers and defibrillators
  • No affiliation to the French health insurance system
  • Under curatorship
  • Imprisoned
  • Known or suspected to be pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    PROTECT Diaphragm Pacing Therapy

    Device: Lungpacer PROTECT Diaphragm Pacing Therapy

Interventions

  • DeviceLungpacer PROTECT Diaphragm Pacing Therapy

    PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.

    Also known as: Lungpacer PROTECT DPTS

06

What researchers measure

Primary outcomes

  1. Changes in PaO2/FiO2 ratio

    The changes in PaO2/FiO2 ratio during each acute standard of care ventilation and acute PROTECT pacing therapy session.

    Time frame: Day 1

Secondary outcomes

  1. Successful LIVE catheter placement

    LIVE Catheter was successfully inserted into the left subclavian vein, positioned in accordance with the LIVE Catheter IFU, and the diaphragm was stimulated.

    Time frame: Day 1

  2. Alveolar-arterial (A-a) gradient

    Alveolar-arterial (A-a) gradient documenting gas exchange during each acute standard of care ventilation and acute PROTECT pacing therapy session.

    Time frame: Day 1

  3. Cardiac output index

    Pulse contour cardiac output index assessed by transpulmonary thermodilution during each acute standard of care ventilation and acute PROTECT pacing therapy session.

    Time frame: Day 1

  4. Regional lung ventilation

    Regional lung ventilation assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.

    Time frame: Day 1

  5. Regional lung atelectasis

    Regional lung atelectasis assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.

    Time frame: Day 1

  6. Serious adverse events

    Occurrence of pneumothorax, significant bleeding and desaturation serious adverse events.

    Time frame: Day 5

Other outcomes

  1. Days until successful weaning

    Time frame: Day 5

  2. Mortality

    Time frame: Day 5

07

Study locations

1 site
  • Hôpital La Pitié-Salpêtrière
    Paris, 75651, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Feb 2023, 17 months.

Of 273 interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 14, 2021
StartActual
Aug 25, 2021
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 13, 2023
Last update
Oct 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04844892
Lead sponsor
Lungpacer Medical Inc.
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Aug 25, 2021
Primary completion
Feb 1, 2023
Completion
Feb 13, 2023
Last update
Oct 5, 2023

Study contacts

Martin Dres, MD
principal investigator · AP-HP Hôpital La Pitié-Salpêtrière

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion